This invention relates to a pharmaceutical composition useful in the treatment of arterial thrombosis. A combination of a non-steroidal anti-inflammatory agent with a benzisothiazolone of formula (I) is found to be capable of inhibiting the aggregation of blood platelets to a greater degree than each of the components separately.
R1 and R2 represent a variety of substituent groups; X represents a bond or an alkylene chain; and R represents a heterocyclic group.
When the anti-inflammatory agent contains a carboxylic acid group, the combination with compound (I) may be in the form of a salt.
BAGGALEY, K. H.;ENGLISH, P. D.;JENNINGS, L. J. A.;MORGAN, B.;NUNN, B.;TYR+, J. MED. CHEM., 1985, 28, N 11, 1161-1167
作者:BAGGALEY, K. H.、ENGLISH, P. D.、JENNINGS, L. J. A.、MORGAN, B.、NUNN, B.、TYR+
DOI:——
日期:——
TYRRELL, A. W. R., TETRAHEDRON LETT., 1985, 26, N 14, 1753-1756
作者:TYRRELL, A. W. R.
DOI:——
日期:——
US4186203A
申请人:——
公开号:US4186203A
公开(公告)日:1980-01-29
Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen
作者:Keith H. Baggaley、Peter D. English、L. John A. Jennings、Brian Morgan、Barbara Nunn、A. William R. Tyrrell
DOI:10.1021/jm00149a021
日期:1985.11
and the compounds were tested for ability to inhibitplateletaggregation induced by adenosine diphosphate and collagen in rats and guinea pigs ex vivo. Alkyl substituents at the 2-position bearing a basic group were necessary for ex vivo activity. Several of the compounds were potent inhibitors of adenosine diphosphate induced first-phase aggregation, but adverse toxicological findings terminated